¹³¹I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma

Abstract

Combination of (131)I-metuximab and TACE prolonged the survival time in patients with HCC compared with TACE alone. The combination treatment was safe and effective.

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

“…136,137 For instance, iodine ( 131 I) metuximab injection (Licartin ® ), a 131 I-labeled HAb18G/CD147-specific monoclonal antibody (mAb) F(ab') 2 fragment, has been approved for the treatment of primary HCC by the China State Food and Drug Administration. 138 The HAb18G/ CD147, an antigen for being homologous to CD147, is highly expressed on HCC cells and tissues and can bind to the bivalent fragment HAb18 F(ab') 2 of HAb18 mAb with high affinity. 139 Jin et al 140 fabricated the DOX-poly(d,llactic-co-glycolic acid)-poly(ethylene glycol) (DOX-PLGA-PEG) micelle and further decorated with bivalent fragment HAb18 F(ab') 2 to improve the therapeutic effect for HCC, demonstrating that the cellular uptake was enhanced through antigen-antibody recognition between the micelle and tumor cells, and the therapeutic action was improved due to higher accumulation of DOX in tumor cells.…”

Transcatheter Arterial Chemoembolization Plus131I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

“…The full-texts were carefully evaluated. They were published from 2007 to 2015, and all had investigated TACE plus 131 I-metuximab therapy (1112131920212223). Totally 1121 patients were included in these studies.…”

“…Among those, 546 patients underwent TACE plus 131 I-metuximab therapy, as compared with 575 patients who received TACE alone. There were: 3 RCTs (112223), and 5 non-RCTs (1213192021) (Fig. 1).…”

“…S20050039) (10). Initially, 131 I-metuximab monotherapy has reported to be effective in preventing the tumor recurrence after orthotopic liver transplantation (11), but conversely, He et al (12) and Wang et al (13) reported that 131 I-metuximab treatment showed no significant difference in 1-year overall survival (OS). 131 I-metuximab has been used as an adjuvant therapy to TACE in some of the clinical studies, however, these trials were usually small and their results were inconsistent.…”

Will cancer cells be defeated by sodium bicarbonate?

“…A radiolabelled therapeutic antibody against CD147 (metuximab) has been tested in clinical trials in China. In combination with TACE, metuximab significantly improved the survival of advanced HCC patients in a non-randomized control trial (He et al, 2013). If the survival benefit of TILA-TACE is further confirmed by additional trials and becomes a routine practice, the expensive antibody-based therapy will have a hard time to compete TILA-TACE for local and intermediate stage HCC, but it may have utility for extrahepatic spread in the advance stage of HCC.…”